drugset / Trial / NCT02917941
A Study of Ixazomib Plus Lenalidomide and Dexamethasone in Adult Japanese Participants With Relapsed and/or Refractory Multiple Myeloma
NaSingle-groupOpen-labelTreatment
Summary
The purpose of this study is to evaluate the efficacy and safety of ixazomib plus lenalidomide and dexamethasone in Japanese participants with relapsed and/or refractory multiple myeloma (RRMM).
Timeline
- Start
- 2016-11-01
- Primary completion
- 2019-08-31
- Completion
- 2019-08-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Ixazomib | Unknown | 4 mg | Oral |
| Background | Dexamethasone | Small molecule | 40 mg | Oral |
| Background | Lenalidomide | Other / unclassified | 10 mg | Oral |
| Background | Lenalidomide | Other / unclassified | 15 mg | Oral |
| Background | Lenalidomide | Other / unclassified | 25 mg | Oral |